SCHEMBL3566503

SCHEMBL3566503

O=C(NCCO)c1ccc2c3c(cc([N+](=O)[O-])c2c1)NCC3CCl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
HPGD P15428 3/20 0.39
KDM4E B2RXH2 3/20 0.39
HTT P42858 4/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
HSP90AA1 P07900 1/20 0.38
TP53 P04637 1/20 0.38
CASP1 P29466 1/20 0.38
MAPT P10636 7/20 0.37
MAPK1 P28482 3/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GSTP1 P09211 1/20 0.36
GSTM2 P28161 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 3/20 0.36
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567311 0.89 SMN1; SMN2 (0.45) ALDH1A1HPGDKDM4EHTTSMN1; SMN2
SCHEMBL3569002 0.85 SMN1; SMN2 (0.45) ALDH1A1HPGDKDM4EHTTSMN1; SMN2
SCHEMBL3570106 0.83 PARP1 (0.40) ALDH1A1HTTPOLBSMN1; SMN2TP53
SCHEMBL3558765 0.83 VCAM1 (0.41) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL3565636 0.81 MAPK1 (0.39) ALDH1A1KDM4EHTTMAPTMAPK1
SCHEMBL3562739 0.80 CASP6 (0.42) POLBLMNA
SCHEMBL3569084 0.79 PARP1 (0.40) ALDH1A1HTTPOLBSMN1; SMN2TP53
SCHEMBL3556964 0.79 VCAM1 (0.41) ALDH1A1HPGDHTTSMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL3560929 0.79 KMT2A (0.36) ALDH1A1HPGDKDM4EHTTPOLB
SCHEMBL3568374 0.78 ALDH1A1 (0.37) ALDH1A1HPGDSMN1; SMN2HSP90AA1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A ALDH1A1 77/4885HPGD 16/4885KDM4E 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.